Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a challenging multi-system global health problem, affecting approximately one-third of the world's population. Lifestyle modifications remain the cornerstone of MASLD management, which poses challenges in this population. The recent US Food and Drug Administration approval of resmetirom and semaglutide for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis signifies a substantial transformation in the therapeutic landscape. Other new therapeutic options are emerging, with encouraging phase 3 data from several agents spanning diverse mechanisms of action. This review summarizes the contemporary non-pharmacological and pharmacological approaches to MASLD.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.